1. Home
  2. YSG vs VYGR Comparison

YSG vs VYGR Comparison

Compare YSG & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

YSG

Yatsen Holding Limited

HOLD

Current Price

$3.02

Market Cap

283.5M

ML Signal

HOLD

Logo Voyager Therapeutics Inc.

VYGR

Voyager Therapeutics Inc.

HOLD

Current Price

$3.96

Market Cap

236.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
YSG
VYGR
Founded
2016
2013
Country
China
United States
Employees
N/A
N/A
Industry
Package Goods/Cosmetics
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
283.5M
236.0M
IPO Year
2020
2015

Fundamental Metrics

Financial Performance
Metric
YSG
VYGR
Price
$3.02
$3.96
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$21.00
AVG Volume (30 Days)
159.7K
900.2K
Earning Date
05-15-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$10,135,000.00
Revenue This Year
$23.08
$33.19
Revenue Next Year
$9.45
$14.68
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.87
$2.65
52 Week High
$11.04
$5.55

Technical Indicators

Market Signals
Indicator
YSG
VYGR
Relative Strength Index (RSI) 35.33 48.30
Support Level $2.87 $3.72
Resistance Level $4.39 $4.30
Average True Range (ATR) 0.25 0.21
MACD -0.03 -0.02
Stochastic Oscillator 9.52 51.75

Price Performance

Historical Comparison
YSG
VYGR

About YSG Yatsen Holding Limited

Yatsen Holding Ltd is engaged in the retail business of beauty products, skincare items, and other cosmetic products. The group's principal operations are currently organized into three segments on a product category basis, namely Color Cosmetics Brands, Skincare Brands, and others. The company's majority of revenue is generated from sales of Color Cosmetics Brands.

About VYGR Voyager Therapeutics Inc.

Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.

Share on Social Networks: